On 22. April 2025, Ypsomed and TecMed AG (TecMed) announced that they had entered into an agreement for the sale of Ypsomed’s diabetes care business for up to CHF 420 million, including earn-out. TecMed is a company based in Burgdorf, controlled by Willy Michel. Ypsomed is focusing on strengthening its leading position in the market for subcutaneous self-injection solutions for pharmaceutical and biotech companies.
Ypsomed is selling Ypsomed Diabetes Care AG, including the relevant subsidiaries, the patch pump development activities and related rights to TecMed. The transaction is expected to close in the second half of 2025, subject to regulatory approvals of the ongoing carve-out. The sale proceeds will finance Ypsomed’s expansion of the injection system business.
Ypsomed is convinced that two specialized companies will be more focused, more agile, and therefore, more successful in the long term.
